Sponsor:
BeiGene
Code:
NCT05100862
Conditions
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Zanubrutinib
Rituximab
Lenalidomide
Obinutuzumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations